Laura Shawver's most recent trade in ARS Pharmaceuticals Inc was a trade of 30,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 12.30 per share. | 07 Apr 2025 | 50,002 | 210,346 | - | 12.3 | 615,075 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.85 per share. | 07 Apr 2025 | 27,493 | 260,348 | - | 4.8 | 133,341 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 27,493 | 24,062 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.85 per share. | 07 Apr 2025 | 22,509 | 232,855 | - | 4.9 | 109,169 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 22,509 | 51,555 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 11.21 per share. | 05 Mar 2025 | 49,600 | 210,346 | - | 11.2 | 556,046 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.85 per share. | 05 Mar 2025 | 49,600 | 259,946 | - | 4.9 | 240,560 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 49,600 | 74,064 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 400 | 123,664 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 11.00 per share. | 05 Mar 2025 | 400 | 210,346 | - | 11 | 4,400 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.85 per share. | 05 Mar 2025 | 400 | 210,746 | - | 4.9 | 1,940 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 12.31 per share. | 03 Feb 2025 | 50,000 | 210,346 | - | 12.3 | 615,565 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 40,936 | 124,064 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.85 per share. | 03 Feb 2025 | 40,936 | 260,346 | - | 4.9 | 198,540 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.15 per share. | 03 Feb 2025 | 9,064 | 219,410 | - | 3.2 | 28,552 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 9,064 | 0 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.15 per share. | 06 Jan 2025 | 50,000 | 260,346 | - | 3.2 | 157,500 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 50,000 | 9,064 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 11.10 per share. | 06 Jan 2025 | 50,000 | 210,346 | - | 11.1 | 555,065 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 13.55 per share. | 02 Dec 2024 | 96,343 | 211,247 | - | 13.6 | 1,305,823 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 13.26 per share. | 02 Dec 2024 | 87,984 | 210,346 | - | 13.3 | 1,166,897 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 02 Dec 2024 | 67,616 | 277,962 | - | 1.3 | 85,872 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 67,616 | 0 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.15 per share. | 02 Dec 2024 | 62,378 | 298,330 | - | 3.2 | 196,491 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 62,378 | 73,836 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 02 Dec 2024 | 29,628 | 307,590 | - | 1.3 | 37,628 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 29,628 | 25,606 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 02 Dec 2024 | 25,606 | 235,952 | - | 1.3 | 32,520 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 25,606 | 0 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.15 per share. | 02 Dec 2024 | 14,772 | 225,118 | - | 3.2 | 46,532 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 13.75 per share. | 02 Dec 2024 | 14,772 | 210,346 | - | 13.7 | 203,109 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 14,772 | 59,064 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 14.34 per share. | 02 Dec 2024 | 901 | 210,346 | - | 14.3 | 12,922 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Relay Therapeutics Inc | Laura Shawver | Director | 03 Jun 2024 | 102,225 | 102,225 | - | - | Stock Option (Right to Buy) | ||
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 03 Aug 2023 | 26,107 | 236,453 | - | 1.3 | 33,156 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 7.01 per share. | 03 Aug 2023 | 26,107 | 210,346 | - | 7.0 | 183,018 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 26,017 | 21,894 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 7.06 per share. | 03 Aug 2023 | 18,897 | 210,346 | - | 7.1 | 133,471 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 03 Aug 2023 | 18,897 | 229,243 | - | 1.3 | 23,999 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 18,897 | 2,997 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 36,281 | 48,001 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 7.09 per share. | 01 Aug 2023 | 36,281 | 210,346 | - | 7.1 | 257,265 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 01 Aug 2023 | 36,281 | 246,627 | - | 1.3 | 46,077 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 7.19 per share. | 01 Aug 2023 | 18,715 | 210,346 | - | 7.2 | 134,576 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 18,715 | 84,282 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 01 Aug 2023 | 18,715 | 229,061 | - | 1.3 | 23,768 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2023 | 33,510 | 111,855 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 03 Jul 2023 | 33,510 | 243,856 | - | 1.3 | 42,558 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 6.34 per share. | 03 Jul 2023 | 33,510 | 210,346 | - | 6.3 | 212,554 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 03 Jul 2023 | 31,112 | 241,458 | - | 1.3 | 39,512 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 6.41 per share. | 03 Jul 2023 | 31,112 | 210,346 | - | 6.4 | 199,552 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2023 | 31,112 | 145,365 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 03 Jul 2023 | 26,520 | 236,866 | - | 1.3 | 33,680 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 6.72 per share. | 03 Jul 2023 | 26,520 | 210,346 | - | 6.7 | 178,347 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2023 | 26,520 | 176,477 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Relay Therapeutics Inc | Laura Shawver | Director | 31 May 2023 | 66,055 | 66,055 | - | - | Stock Option (Right to Buy) | ||
| Relay Therapeutics Inc | Laura Shawver | Director | 24 May 2023 | 12,099 | 40,000 | - | - | Common Stock | ||
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 09 Nov 2022 | 57,100 | 267,446 | - | 1.3 | 72,517 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 6.16 per share. | 09 Nov 2022 | 57,100 | 210,346 | - | 6.2 | 351,736 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2022 | 57,100 | 345,897 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 4.58 per share. | 09 Nov 2022 | 43,896 | 210,346 | - | 4.6 | 201,044 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.27 per share. | 09 Nov 2022 | 42,900 | 253,246 | - | 1.3 | 54,483 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Sale of securities on an exchange or to another person at price $ 5.31 per share. | 09 Nov 2022 | 42,900 | 210,346 | - | 5.3 | 227,799 | Common Stock |
| ARS Pharmaceuticals Inc | Laura Shawver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2022 | 42,900 | 302,997 | - | - | Stock Option (Right to Buy) | |
| Nkarta Inc | Laura Shawver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Relay Therapeutics Inc | Laura Shawver | Director | 27 May 2022 | 41,597 | 41,597 | - | - | Stock Option (Right to Buy) | ||
| Nkarta Inc | Laura Shawver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2021 | 16,511 | 16,511 | - | - | Stock Option (right to buy) |